NYSE · PHARMACEUTICAL PREPARATIONS · LARGE CAP
GSK PLC GSK
11 fiscal years on record · GBP · FY2025 reported · SEC filings only
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Growth
GBP 32.7B
Revenue, FY2025 · full 11-year series below
Revenue £B
Net income £B
FY2025 · Revenue 32.7 · Net income 5.7
15B30B
20152018202120242025
Compound annual growth
+3.7%
+6.0%
+3.2%
−27.4%
−0.1%
−3.8%
−27.6%
−0.5%
−2.1%
+2.5%
−8.0%
−1.9%
+17.7%
+0.2%
+0.4%
3 yrs
5 yrs
10 yrs
15 yrs
Revenue compounded at +6.0% a year over the five years to FY2025.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
19 cents
of every revenue dollar became profit
Operating margin
Net margin
FY2025 · Operating 24.3% · Net 19.3%
20%40%
201520202025
ROE
FY2025 · ROE 38.0%
50%100%
201520202025
Three returns, three denominators.
Each GBP of equity produced 38 cents of profit this year.
The 11-year record
11 fiscal years
Every figure from documents filed with the SEC · GBP
row low → row highnegative—not applicable◌not available in our data
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue £B | 32.7 | 31.4 | 30.3 | 29.3 | 24.7 | 24.4 | 33.8 | 30.8 | 30.2 | 27.9 | 23.9 |
| Operating income £B | 7.9 | 4.0 | 6.7 | 6.4 | 4.4 | 6.0 | 7.0 | 5.5 | 4.1 | 2.6 | 10.3 |
| EBITDA £B | 10.2 | 6.6 | 9.0 | 8.6 | 6.5 | 8.0 | 9.3 | 7.3 | 6.0 | 4.4 | 12.0 |
| Income tax £B | 1.1 | 0.5 | 0.8 | 0.7 | 0.1 | 0.1 | 1.0 | 0.8 | 1.4 | 0.9 | 2.2 |
| Net income £B | 5.7 | 2.6 | 4.9 | 15.0 | 4.4 | 5.7 | 4.6 | 3.6 | 1.5 | 0.9 | 8.4 |
| Free cash flow £B | 6.4 | 5.2 | 5.5 | 6.3 | 7.0 | 7.5 | 6.8 | 7.1 | 5.4 | 5.0 | 1.2 |
| EPS, diluted £ | 1.39 | 0.62 | 1.20 | 3.66 | 1.08 | 1.43 | 0.93 | 0.73 | 0.31 | 0.19 | 1.72 |
| Dividend / sh £ | 0.66 | 0.61 | 0.58 | 0.61 | 1.00 | 1.00 | 80.00 | 80.00 | 80.00 | 0.80 | 0.80 |
| Payout % | 47 | 97 | 48 | 17 | 91 | 69 | 85 | 109 | 256 | 427 | 46 |
| ROE % | 38.0 | 19.1 | 41.2 | 116.6 | 29.6 | 44.2 | 61.2 | — | — | 81.1 | ◌ |
Slide the table for earlier years. "—" not applicable · "◌" not available in our data.
Provenance
Company facts, as filed
How we verify · 1 failure in 53 reconciliationsAUDITED
Reconciled in 10 of the 11 fiscal years we could check. 18 checks were skipped: the balance sheet is not tagged before 2016. Eight checks were skipped: EPS is not tagged before 2015. Eight checks were skipped: revenue is not tagged before 2015.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency1 failure
ActivityPharmaceutical Preparations
Listed onNYSE
Incorporated inoutside the United States — SEC code X0
Fiscal year endsnot stated in the filings
Data on record since2015